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1. Introduction
A primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodg‐
kin’s lymphoma arising in the craniospinal axis. For many years, PCNSLs were reported to
represent 3–5% of all primary central nervous system (CNS) tumors [1]. However, PCNSL
appears to be increasing in incidence [2-4]. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-
fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33% increase) for the
same registries over the same time periods [2]. The increase is evident in all age groups and
in both genders [2]. The tumor manifestation is often diffuse and multifocal, and most fre‐
quently affects the supratentorial brain parenchyma. The absence of systemic lymphadeno‐
pathies and other extracranial localizations of disease should be confirmed. Most PCNSLs
belong to the diffuse large B-cell lymphomas (DLBCLs), but differ from systemic DLBCLs by
their less favorable prognosis. The systemic use of high-dose methotrexate (HD-MTX)-based
chemotherapy with radiation therapy for newly diagnosed PCNSL has improved the me‐
dian overall survival (OS) from 20 to 36 months [5-8]. However, more intense efforts are re‐
quired to improve the outcome of the patients and to identify novel therapeutic strategies.
In this article, we will review the recent developments of basic and clinical research on
PCNSL.
2. Clinical characteristics
PCNSL has been described at all ages, but usually arise in the fifty to sixty years, with a
male to female ratio of 1.5 [9]. The symptoms are focal neurological deficits, mental disturb‐
ance and increased intracranial pressure. The characteristics of radiographic findings of
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PCNSL are homogenous contrast enhancement on MRI with gadolinium at least 15 mm in
contact with the subarachnoid space [10], periventricular lesions involving the corpus callos‐
um, basal ganglia, or thalamus. The eye is involved in about 20% of patients [11]. Leptome‐
ningeal involvement is seen in about 18% [12]. The tumor is single in 60% of patients and
multiple in the remainder [10]. Diffusion-weighted MRI (DW-MRI) and proton-MR-spectro‐
scopy (1H-MRS) usually reveal a uniformly pathologic pattern of metabolite concentrations
[10]. The absence of systemic lymphadenopathies and other extracranial localizations of dis‐
ease should be confirmed. Corticosteroids can temporaly cause regression of the tumor in
40-85% of patients [13]. Diagnosis requires histologic conformation. Molecular analysis of
the rearrangement of immunoglobulin heavy chain genes by means of polymerase chain re‐
action (PCR) and Southern blotting may be acceptable [14]. Most PCNSLs belongs to diffuse
large B cell and phenotypically express pan-B-cell markers such as CD19, CD20, CD22 and
CD79a. The majority of PCNSL express BCL-6, a marker of GCB (germinal center B-cell-like)
cells, and MUM1, a marker of late GCB cells.
3. Treatment
PCNSL is sensitive to radiation therapy, however patients treated with radiotherapy alone
had 5-year over all survivals of 3-4%, more than 80% patients relapsed within 10-14 months
[15]. Standard radiotherapy for patients consists of 40 Gy to whole brain with an additional
boost of 10-20 Gy on the tumor bed [16]. Shibamoto et al. [17] reported the recent improved
results of radiation monotherapy, 5-year survival was 25% for patients 63 years old or
younger, and 9.8% for those older than 63 years. Since total irradiation dose is an important
predictor of delayed neurotoxicity, a decrease in the incidence of this complication should
be expected if the total irradiation dose is reduced. Several studies have demonstrated that
HD-MTX, with or without other chemotherapeutic agents, yielded high response rates with
33-45 months over all survival. These results are better than the results of radiotherapy
alone. HD-MTX is widely recognized as the single most effective chemotherapeutic agent
for PCNSL [18-23]. MTX is usually administered at high doses with various schedules. Re‐
cently, randomized trials for PCNSLs are reported. Ferreri et al. [6] assessed the effect of
adding high-dose cytarabine to methotrexate in patients with newly diagnosed PCNSL in
randomised phase 2 trial. Seventy-nine patients with PCNSLs were randomly divided to re‐
ceive four courses of either methotrexate 3.5 g/m2 on day 1 (n=40) or methotrexate 3.5 g/m2
on day 1 plus cytarabine 2 g/m2 twice a day on days 2-3 (n=39). Both regimens were admin‐
istered every 3 weeks and were followed by whole-brain radiotherapy (WBRT). After che‐
motherapy, seven patients given methotrexate and 18 given methotrexate plus cytarabine
achieved a complete remission, with a complete remission rate of 18% and 46% (p=0.006),
and a 3-year OS of 32% and 46% (p=0.07) respectively. In patients aged 75 years and young‐
er with PCNSL, the addition of high-dose cytarabine to high-dose methotrexate provides
improved outcome with acceptable toxicity compared with high-dose methotrexate alone.
Thiel et al. [8] aimed to investigate whether first-line chemotherapy based on high-dose me‐
thotrexate was non-inferior to the same chemotherapy regimen followed by WBRT for over‐
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all survival. Patients received high-dose methotrexate (4 g/m2) on day 1 of six 14-day cycles;
thereafter, patients received high-dose methotrexate plus ifosfamide (1.5 g/m2) on days 3-5
of six 14-day cycles. In those assigned to receive first-line chemotherapy followed by radio‐
therapy, WBRT was given to a total dose of 45 Gy. 551 patients (median age 63 years) were
enrolled and randomised, of whom 318 were treated per protocol. In the per-protocol popu‐
lation, median OS was 32.4 months in patients receiving WBRT (n=154), and 37.1 months in
those not receiving WBRT (n=164), hazard ratio 1.06 (p=0.71). Median progression-free sur‐
vival (PFS) was 18.3 months in patients receiving WBRT, and 11.9 months (p=0.14) in those
not receiving WBRT. Treatment-related neurotoxicity in patients with sustained complete
response was more common in patients receiving WBRT than in those who did not. No sig‐
nificant difference in OS was recorded when WBRT was omitted from first-line chemothera‐
py in patients with newly diagnosed PCNSL. The PFS benefit afforded by WBRT has to be
weighed against the increased risk of neurotoxicity in long-term survivors. The results of
this trial may indicate that WBRT can be omitted from first-line treatment of PCNSL.
4. Neurological toxicity
As survival of patients with PCNSL becoming long, the quality o life and mental function is
now very important. Neurotoxicity typically is associated with significant cognitive, motor
and autonomic dysfunction, and has a negative impact on quality of life. Delayed neurologic
toxicity is a serious complication, especially occurring in patients older than 60 years [24].
MTX is a known neurotoxin and has the potential of producing leukoenceohalopathy as
well as other types of neurotoxicities such as microangiopathy [25]. MTX is a folate antago‐
nist inhibiting nucleic acid and methioine synthesis. Methionine is necessary for CNS myeli‐
nation. The presence of a risk haplotype defined by polymorphisms influencing methionine
metabolism referred a relative risk for CNS white matter changes [26]. MTX in combination
with WBRT relates to its potential for causing delayed leukoencephalopathy. Radiation ther‐
apy prior to MTX administration increase the risk of leukoencephalopathy. While intrathe‐
cal, intravenous MTX and WBRT have the potential for producing leukoencephalopathy
independently, when two or three of them are combined the risk will increase [27]. Nguyen
et al. [28] reported late treatment-associated neurotoxicity in 15% of patients and was signifi‐
cantly associated with total radiation doses greater than 36 Gy. O`Brien et al. [29] reported
30% of neurotoxicity risk who were treated with MTX (1g/m2) followed by WBRT. For pa‐
tients aged>60 years the risk of neurotoxicity at 7 years was 58%. Correa et al. [30] reported
the neuropsychological evaluation of 28 patients. These were of sufficient severity to reduce
quality of life in half of the patient sample. Patients treated with WBRT+/- chemotherapy re‐
vealed more pronounced cognitive impairement, particularly in the memory and attention/
executive domain. Extent of white matter disease correlated with attention/executive, mem‐
ory, and language impairment. PCNSL survivors treated with WBRT+/- chemotherapy dis‐
played more pronounced cognitive dysfunction than patients treated with MTX-based
chemotherapy alone. Omuro et al. [31] described delayed neurotoxicity, analyzing 185
PCNSL patients. The 5-year cumulative incidence of neurotoxicity was 24%. Neurotoxicity
Primary Central Nervous System Lymphoma − Recent Advance on Clinical Research
http://dx.doi.org/10.5772/52757
463
presented as a rapidly progressive subcortical dementia characterized by psychomotor
slowing, executive and memory dysfunction, behavioral changes, gait ataxia, and inconti‐
nence. Imaging findings revealed diffuse white matter disease and cortical-subcortical atro‐
phy. Available autopsy data showed white matter damage with gliosis, thicking of small
vessels, and demyelination. Older age, mental status changes at diagnosis, female sex, and
radiotherapy predicted neurotoxicity on univariate analysis, but only radiotherapy re‐
mained significant in the multivariate setting. They conclude that the core pathophysiologi‐
cal mechanism is the interruption of frontal-subcortical circuits mediated by radiation
damage, possibly caused by microvascular alterations, loss of oligodendrocyte progenitors,
or oxidative stress. Fliessbach et al. [32] reported the impact of HD-MTX based chemothera‐
py alone on long term cognition and quality of life in patients with PCNSL. The median fol‐
low-up period was 44 months after diagnosis. In long-term follow-up 22 (95%) of 23 patients
showed either preserved or improved cognitive functions as compared with pretreatment
and immediate posttreatment baseline assessment. Eleven (48%) of 23 patients displayed at
least mild cognitive deficits at long-term follow-up not related to therapy. Nineteen (83%) of
23 patients reported a good quality of life (QOL). They conclude that in patients with
PCNSL treated with MTX-based chemotherapy alone, no gross cognitive decline has to be
expected as a long-term treatment effect. Finally, formal neuropsychological examination
guideline in PCNSL clinical trial should be established in the future.
5. Molecular biomarker
There are still many individual variations within the diagnostic and prognostic categories,
resulting in a need for additional molecular biomarkers, partly because of the inability to
recognize these patients prospectively. Although the clinical scoring model using age, Kar‐
nofsky Performance Status (KPS), and lactate dehydrogenase (LDH) level has prognostic
value for PCNSL [33-35], it has not been used successfully to stratify patients for therapeutic
trials. Molecular markers could improve the outcome prediction, discover potential targets
for therapeutic intervention, and elucidate mechanisms that result in resistance to chemo‐
therapy. The reason little progress in molecular analyses of PCNSL has been achieved so far
is the very tiny sample amounts obtained for genetic analyses. A better understanding of
PCNSL biology is crucial to improve its prognosis. However, only a few studies have been
reported on gene expression profiles of PCNSLs. Rubenstein et al. [36] compared the gene
expression signature of 23 PCNSL patients with that of nine nodal large B-cell lymphoma
patients. They showed that individual cases of PCNSL were classified as GCB cell, ABC (ac‐
tivated B-cell-like) cell, or type 3 large B-cell lymphoma based on the cell-of-origin classifica‐
tion described by Alizadeh et al [37]. In addition, PCNSLs were distinguished from nodal B-
cell lymphoma by high expression of regulators of the unfolded protein response signaling
pathway by c-Myc and Pim-1. The IL-4 signaling pathway is associated with tumorigenesis
and adverse prognosis in PCNSL patients [36]. Montesinos-Rongen et al. [38] reported the
gene expression profile of 21 PCNSLs. They showed that PCNSLs resembled late GCB cells
in their gene expression pattern, and that PCNSLs were distributed among the spectrum of
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systemic DLBCLs. Tun et al. [39] reported a gene expression comparison between 13
PCNSLs and 30 non-CNS DLBCLs. PCNSL was characterized by significant expression of
multiple extracellular matrix- and adhesion-related pathways. Sung et al. [40] evaluated 12
PCNSL patients by comparative genomic hybridization and 7 out of the 12 patients by ex‐
pression profiling. They selected eight candidate genes in which expression changes were
associated with copy number changes.
Systemic DLBCLs comprise several diseases that differ in responsiveness to chemotherapy
[41,42]. The GCB cell-like subgroup expressed genes characteristic of normal GCB cells and
were associated with a good outcome, whereas the ABC cell-like subgroup expressed genes
characteristic of activated B cells and were associated with a poor outcome. Gene expression
analyses of PCNSLs have largely focused on normal lymphocyte development, and the cell-
of-origin classification method was investigated so far. Kawaguchi et al. [43] developed a
novel scoring system based on molecular markers. Expression profiling was performed on
32 PCNSLs. A gene classifier with 23 genes was developed using the random survival for‐
ests model. Based on this, Prognosis Prediction Score using immunohistochemical analysis
is also developed and validated in another data set. Among the genes, BRCA1 protein ex‐
pression was most strongly associated with patient survival. They have identified gene ex‐
pression signatures that can accurately predict survival in patients with PCNSL.
6. Conclusion
Much more aggressive therapies, such as high-dose chemotherapy with stem cell implanta‐
tion [44] or molecular targeted therapies that specifically target disabled pathways, might be
tailored in those patients with a poor prognosis. In this regard, molecular biomarkers might
not only predict the likelihood of short-term survival, but also yield clues on individual
genes involved in tumor development, progression, and response to therapy. Moreover, the
ability to distinguish PCNSLs will enable appropriate therapies to be tailored to specific tu‐
mor subtypes. Class prediction models based on defined molecular profiles allow classifica‐
tion of PCNSLs in a manner that will be better correlated with clinical outcomes. Therefore,
identification of these molecular subclasses of PCNSLs could greatly facilitate prognosis pre‐
diction and ability to develop effective treatment protocols.
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